Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of LiRIS 400 mg in Women With Ulcerative Interstitial Cystitis

Trial Profile

A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of LiRIS 400 mg in Women With Ulcerative Interstitial Cystitis

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 May 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lidocaine (Primary)
  • Indications Interstitial cystitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Allergan; TARIS Biomedical
  • Most Recent Events

    • 10 May 2016 Results of safety, tolerability and preliminary efficacy of LiRIS(R) 400 mg presented at the 111th Annual Meeting of the American Urological Association.
    • 24 Nov 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 08 May 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top